by 1horsetown
Alzheimer’s excitement? Try, try again
[Via Knight Science Journalism Tracker]
It was a good drug, an important drug, maybe the drug. It was the drug that might finally bring Alzheimer’s disease to heel.
A study of Russian subjects published in The Lancet in 2008 found that the drug, dimebon, “significantly improved the clinical course of patients with mild-to-moderate Alzheimer’s disease.”
“Dimebon shines as Alzheimer’s therapy,” Daniel J. DeNoon of WebMD wrote in July, 2008. He went on to say that the drug “is now only one clinical trial away from approval.”
Turns out, it was a rather large step away from approval. The results of that one remaining study were released last week, and the breathless headlines of the summer of 2008 have now crumbled into dust.
The Wall Street Journal, along with many others, reported last week that dimebon was no more effective than a Cinnabon. (The Journal didn’t put it exactly that way.)
The drug, the Journal said, “failed to meet its primary and secondary goals—improving thinking ability and overall daily function over six months in patients with mild-to-moderate Alzheimer’s disease,” according to the Journal’s newswire.
Robert Langreth at Forbes went further, dissecting the hype. While the media were parroting the claim that this could be the first drug to slow the course of Alzheimer’s disease, others were suspicious.
[More]
Paul asks a great question here about whether the reporters that helped hype the story will pay any price. Not so much since they were successful. They sold papers. Being balanced or cautious is really secondary. That does not help sell the story.
The hype never rubs off on the reporters. Who will be made to look bad here are the ‘scientists.’ Not just the ones who fed the hype but also the scientists who urged caution. Because reporters will not really separate them out for the readers.
It will just be one more reason for people to not believe what scientists say. It helps feed the misrepresentation of research that is so valuable to vested interests. Researchers lose their reputation but I have yet to see a reporter lose theirs because of the hyped science they write about.
The pundits who get the most airtime on TV are not those that provide a balanced view. They are those that present a one-sided, sometime hysterical view, hyping their points as much as possible.
It is just a shame when it is people’s lives that are involved. This is why double-blind clinical trials are done. So that the truth can penetrate the hype. With little help from reporters.
That is why sites such as the KS journalism tracker are really useful. Because they provide a place for reporters to be held accountable.
And if you want a really great place to learn about research and hype in a rational, balanced way, check out the National Health Services Choices Behind the Headline pages. They have a great format to provide real information without the hype. It maintains perspective.